ance
Results will be presented from an analysis of wrinkle morphology and dynamic skin strain in the RELAX and EXPRESSION trials investigating Relfydess – the first and only ready-to-use liquid neuromodulator created with PEARLTMTechnology.12,14Results reinforce its onset of action as early as Day 1 in patients with moderate-to-severe frown lines and crow’s feet, with sustained improvements for six months.12Expert-led consensus recommendations will also be shared addressing important unmet needs in real-world clinical practice and providing clear guidance for the practical use of Relfydess, helping healthcare professionals select the optimal treatment protocol for their patients.15

Spearheading community education and awareness around unmet patient needs
Galderma will also present findings from a global survey of over 4,300 women across five continents linking menopause to several skin changes, including wrinkles, loss of firmness, dryness and dull skin,
=*=*=*=*=*=
当前为第7/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页